Cell free DNA isolation and extraction market is anticipated to grow over $442.8 Million with 14,638.3 Thousand units by 2026.
Biomarker play an important role in development of translational medicine, which facilitates translation of basic research into medical advances. In line with this, most pharmaceutical and biotechnology companies are committing to associate their therapeutic drugs with diagnostic assays to monitor the drug response as number of biomarkers are directly associated with drugs. For instance, Thermo Fisher Scientific in collaboration with Novartis AG, Pfizer Inc. and GlaxoSmithKline Plc. is developing multi-market universal next-generation sequencing for multiple companion diagnostic programs, which will help pharma companies to match cancer patients with specific drug candidate
Early detection of cancer requires suitable diagnostic procedures to screen asymptomatic population which is on average risk of cancer, particularly for breast cancer, cervical cancers, colon cancers and melanoma. Increasing awareness of early signs and symptoms of cancer among physicians and other healthcare professionals as well as among general population. Governments in developed countries such as the U.S. raise funds for cancer research to aid in the diagnosis and treatment. Clinical trials are also funded by governments to support companies in developing effective diagnostic tests for cancer. The cell-free DNA isolation and extraction market drivers includes inclusion of cancer screening tests in national cancer screening programs, increasing discretionary funding for cancer research, associating drugs with diagnostic assays, constantly growing list of cancer biomarkers, exploring next-generation sequencing techniques for cancer diagnostics and others. Market restrains includes lack of standardization and appropriate controls of cell free DNA kits, insurance coverage and reimbursement issues and enormous R&D investment with no therapeutic result.
The global cell free DNA isolation and extraction market is anticipated to grow over $442.8 Million with 14,638.3 Thousand units by 2026, aided by the rising demand for non-invasive prenatal testing among high risk pregnant women and increased demand for liquid biopsy. North America is the leading contributor to the global cell free DNA isolation and extraction market, in terms of both, volume and revenue. The contribution of North America to the global cell free DNA isolation and extraction market was volume and valued to be approximately 59% and 61% in 2016, respectively. However, Asia Pacific is expected to grow, by volume, at an impressive 21.15% CAGR during the forecast period. The extraction kits hold the largest share of the total cfDNA extraction/isolation market and growing at a double digit CAGR. Furthermore, with magnetic bead-based kits, proteinase and heat treatment are unnecessary, enabling all the processes to be conducted at room temperature. As compared to traditional cfDNA extraction methods, there is also a significant reduction in processing and hands-on time.
Among the applications, non-invasive prenatal testing (NIPT) leads the cfDNA extraction/isolation market share. In 2016, the NIPT segment accounted for 72% of the total market. However, the market share of NIPT segment is expected to decrease substantially during the forecast period owing high market penetration rate of cfDNA technology in the cancer diagnostic and screening application. In 2016, next generation sequencing was the most used downstream quantification technique for cfDNA and accounted for 71% of the total sample processing share and is expected to remain the leading quantification technique in 2026.
This market intelligence report provides a multidimensional view of the global cell free DNA isolation and extraction market in terms of market size and growth potential. This research report aims at answering various aspects of the global cell free DNA isolation and extraction market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion.
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches, regulatory clearance, and certifications, partnerships, collaborations, business expansions as well as mergers and acquisitions, among others. The research report provides a comprehensive analysis of the product sales, and manufacturers, and trend analysis by segments and demand analysis by geographical regions.
The report also profiles companies including several key players, such as Agilent Technologies, Inc., Berry Genomics, BGI Diagnostics, BioCAT GmbH, F. Hoffmann-La Roche AG, GATC Biotech AG., Illumina, Inc., Laboratory Corporation of America, LifeCodexx AG, Merck KGaA, Natera Inc., NIPD Genetics, Norgen Biotek Corp., PreAnalytiX GmbH, Premaitha Health Plc, QIAGEN, Quest Diagnostics, SeraCare Life Sciences, Inc., STRATEC Biomedical AG, Thermo Fisher Scientific, AccuBioMed, Aline Biosciences, BioChain, Bioo Scientific Corporation, COVARIS, INC., Epigentek Group Inc., NeoGenStar LLC, Omega Bio-tek, Inc, Promega Corporation, System Biosciences, LLC., and STRECK, INC., among others.
